Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Change in Cash (2020 - 2025)

Historic Change in Cash for Gain Therapeutics (GANX) over the last 6 years, with Q3 2025 value amounting to $2.1 million.

  • Gain Therapeutics' Change in Cash rose 14325.85% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.2 million, marking a year-over-year decrease of 14164.56%. This contributed to the annual value of -$1.4 million for FY2024, which is 13145.88% down from last year.
  • Latest data reveals that Gain Therapeutics reported Change in Cash of $2.1 million as of Q3 2025, which was up 14325.85% from -$2.4 million recorded in Q2 2025.
  • Over the past 5 years, Gain Therapeutics' Change in Cash peaked at $39.1 million during Q1 2021, and registered a low of -$20.0 million during Q2 2022.
  • Over the past 5 years, Gain Therapeutics' median Change in Cash value was -$2.0 million (recorded in 2023), while the average stood at $70483.6.
  • Over the last 5 years, Gain Therapeutics' Change in Cash had its largest YoY gain of 609756.86% in 2021, and its largest YoY loss of 69526.38% in 2021.
  • Gain Therapeutics' Change in Cash (Quarter) stood at -$4.1 million in 2021, then rose by 13.07% to -$3.6 million in 2022, then soared by 311.01% to $7.5 million in 2023, then crashed by 122.14% to -$1.7 million in 2024, then soared by 226.85% to $2.1 million in 2025.
  • Its Change in Cash stands at $2.1 million for Q3 2025, versus -$2.4 million for Q2 2025 and -$1.3 million for Q1 2025.